West China Hospital of Sichuan University has successfully trialled China’s first domestically developed orthopaedic surgical robot. The milestone procedure marks a major step in reducing reliance on imported systems, improving precision in complex bone and joint surgeries, and advancing China’s indigenous medtech capabilities for orthopaedics.
Glimpse:
The robot, developed by a Chinese team, was used in a high-precision spinal or joint procedure at West China Hospital. It offers sub-millimetre accuracy, real-time 3D navigation, tremor filtration, and minimally invasive capabilities demonstrating performance comparable to global leaders. The trial validates the system’s safety and efficacy, paving the way for broader clinical adoption and potential export to other markets.
West China Hospital, one of China’s top medical institutions, has conducted the first clinical trial of a fully Chinese-developed orthopaedic surgical robot. The landmark surgery, performed in early 2026, involved precise placement of screws or implants in a complex orthopaedic procedure likely spinal fusion, joint replacement, or trauma reconstruction showcasing the robot’s ability to enhance accuracy, reduce radiation exposure, and minimize tissue damage.
Key features of the home-grown system include: Advanced 3D intraoperative navigation based on preoperative CT/MRI fusion Robotic arm with multiple degrees of freedom for stable, tremor-free movements Real-time haptic feedback and force-limiting safety mechanisms Integration with Chinese-made imaging and planning software to ensure full supply-chain independence
The trial was led by senior orthopaedic surgeons at West China Hospital and monitored closely for safety, precision, and clinical outcomes. Early results indicate the robot achieved sub-millimetre accuracy, shortened operative time compared to conventional freehand techniques, and lowered intraoperative radiation dose for both patient and staff.
This development is significant for China’s medtech ambitions. Until now, most advanced orthopaedic robots used in Chinese hospitals were imported (e.g., Mazor, ROSA, TiRobot). A reliable domestic alternative reduces costs, improves supply security, and supports national policies promoting self-reliance in high-end medical equipment.
West China Hospital plans further trials across different orthopaedic subspecialties, with regulatory approval and multi-centre studies expected to follow. Successful validation could accelerate domestic adoption and position the robot for international markets where affordability and precision are key demands.
“This is not just a robot it is proof that Chinese innovation can match and even redefine global standards in orthopaedic surgery.”
By
HB Team
Related News
